Glycotope Gmbh

Glycotype Gmbh

Ute Schöber

Steffen Goletz

Hans Baumeister

Marion Schlangstedt

The present invention relates to a cell line selected from the group consisting of (a) a cell line denominated NM-F9 having the DSMZ accession number DSM ACC2606; (b) a cell line denominated NM-D4 having the DSMZ accession number DSM ACC2605; and subclones of (a) or (b). Additionally, the present invention provides a lysate of the cell lines or a molecule or mixture of molecules obtained from these cell lines as well as dendritic cells loaded with said lysate, co-cultivated or fused with cells from the cell lines, or a molecule or mixture of molecules obtained from these cell lines of the present invention. Moreover compositions, preferably pharmaceutical or vaccine compositions are provided which comprise the cell lines, lysate, molecules, mixture of molecules or dendritic cells of the present invention. In another aspect the present invention relates to methods for producing the aforementioned compositions. Furthermore, methods and uses for vaccination against or treatment or prevention of cancers and/or tumourous diseases are provided.

Tumour cell lines and uses thereof

The present invention relates to a process for the production of an immunogenic compound comprising inducing necrosis by temperature in tumor cells and lysing said necrotic tumor cells so as to obtain a lysate. Furthermore, the invention provides a method for the production of a pharmaceutical composition. Additionally, the invention relates to a pharmaceutical composition comprising a lysate obtainable by the aforementioned process. Moreover, methods and uses for vaccination against cancers, tumorous diseases, infections and/or autoimmune diseases comprising administering the cell lysates of the invention or dendritic cells loaded with the cell lysate loaded to an individual are provided.

Growing community of inventors

Berlin, Germany

Ute Schöber